BODY MASS INDEX AND THE FORMATION OF CARDIOVASCULAR PATHOLOGY IN PATIENTS TREATED WITH SUPPRESSIVE DOSES OF LEVOTHYROXINE
Abstract
One of the most important problems of a long monitoring of the patients operated for thyroid carcinoma and receiving suppressive therapy with levothyroxine is the prevention of the adverse effects of treatment on the cardiovascular system. The purpose of the work is to identify the features of formation of symptoms and signs of cardiovascular diseases, as well as heart rhythm abnormalities in young patients receiving suppressive therapy with levothyroxine depending on their body mass index (BMI). Changes in the heart rate variability in patients with tachycardia and high blood pressure are studied. It is shown that patients with normal and overweight have alternative tendencies in the changes of heart rate and the formation of cardiovascular diseases.
About the Authors
T. A. Mityukova
Institute of Physiology of the National Academy of Sciences of Belarus
Belarus
Ph. D. (Biology), Leading researcher
Belarus
Ph. D. (Biology), Leading researcher
Zh. A. Bezler
Belarusian State Medical University
Belarus
Assistant Professor
Belarus
Assistant Professor
T. A. Leonova
Minsk City Clinical Oncologic Dispensary
Belarus
Ph. D. (Medicine), Head of the Department
Belarus
Ph. D. (Medicine), Head of the Department
S. B. Kohan
Institute of Physiology of the National Academy of Sciences of Belarus
Belarus
Researcher
Belarus
Researcher
E. B. Luzina
Institute of Physiology of the National Academy of Sciences of Belarus
Belarus
Junior researcher
Belarus
Junior researcher
O. E. Poluljah
Institute of Physiology of the National Academy of Sciences of Belarus
Belarus
Researcher
Belarus
Researcher
References
1. Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Pacini F., Schlumberger M., Sherman S. I., Steward D. L., Tuttle R. M. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2009, vol. 19, pp. 1167–1214. doi:10.1089/thy.2009.0110.
2. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J. W. A., Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 2006, vol. 54, pp. 787–803. doi:10.1530/eje.1.02158.
3. Rumiantsev P. O., Kornev S. V., Rumiantseva U. V. Modern principles of levothyroxine therapy after operation of patients with well-differentiated thyroid cancer. Opukholi golovy i shei [Head and neck tumors (HNT)], 2013, no. 2, pp. 5–8. (in Russian)
4. Sukonko O. G., Krasny S. A. (eds.) Algorithms of diagnosis and treatment of malignant neoplasms. Minsk, Professional’nye izdaniia Publ., 2012, pp. 440–451. (in Russian)
5. Ivanov G. G., Sula A. S. ECG dispersion mapping: theoretical fundamentals and clinical practice. Moscow, Tekhnosphera Publ., 2009. 190 p. (in Russian)
6. Artishevsky S. N. Vegetative regulation of the heart rhythm of patients with thyroid cancer on the background of suppressive therapy with L-thyroxine. Minsk, 2004. 20 p.
7. Frolov A. V. Control of adaptation mechanisms of the cardiac activity in hospital and sports. Minsk, Poliprint, 2011. 216 p.
Review
Views: 849
Email this article 